Clinical stage immuno-oncology company Imugene (ASX:IMU) has formally commenced cGMP manufacture of the clinical batch of cancer vaccine KEY-Vaxx for the proposed Phase 1 PD-1 clinical trial, after successfully completing pilot studies.
US-based cGMP manufacturer AmbioPharm Inc. has been appointed.
APi is a full-service peptide manufacturing company headquartered in South Carolina, USA.
KEY-Vaxx is a B-cell peptide cancer vaccine which aims to induce the body to produce polyclonal antibodies that block PD-1 signalling, and potentially produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies that are transforming treatment of a range of cancers.
Shares in Imugene (ASX:IMU) closed 4.76 per cent higher to 2.2 cents.